Company: LBRX
Filing Date: 2025-07-23
Form Type: DRS/A
Source: 0000950123-25-006557
Chunk: 351

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-07-23
Form: DRS/A
Chunk 351
---
 |       |  2,455 |
| Total marketable securities     |     |                              |     — |     |         | 28,312 |     |         |     — |     |       | 28,312 |
| Total assets                    |     | $                            | 7,231 |     | $       | 31,530 |     | $       |     — |     | $     | 38,761 |
| Liabilities                     |     |                              |       |     |         |        |     |         |       |     |       |        |
| Derivative liability - warrants |     |                              |     — |     |         |      — |     |         | 1,557 |     |       |  1,557 |
| Total liabilities               |     | $                            |     — |     | $       |      — |     | $       | 1,557 |     | $     |  1,557 |

Marketable Securities The Company accounts for marketable securities held as “available-for-sale”in accordance with ASC 320, Investments- Debt Securities. The Company classifies these investments as current assets and carries them at fair value. The fair values of the Company’s corporate debt securities are based on prices obtained from independent pricing sources. The fair value of other marketable securities classified within Level 2 is based upon observable inputs that may include benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sidedmarkets, benchmark securities, bids, offers, and reference data including market research publications. Certificate of Deposit The Company’s certificates of deposit are Level 2 instruments. The fair value of such instruments is estimated based on valuations obtained from third-party pricing services that utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable either directly or indirectly. These inputs include interest rate curves, foreign exchange rates, and credit ratings. Note Conversion Feature In August and September 2020, the Company entered into Convertible Promissory Note Purchase Agreements (“2020 Notes”) with a group of lenders who loaned the Company a total of $10.0 million. In October 2022, November 2022, December 2022, and January 2023, the Company entered into Convertible Promissory Note Purchase Agreements (“2022 Notes”) with a group of lenders who loaned the Company a total of $25.7 million. The 2020 Notes and 202